Significant numbers from Fidaxomicin supplies for Biocon are expected in FY2013E. Recently Optimer increased its peak sales forecast to US$2 bn from US$1.5 bn earlier. Biocon has also tied up as the exclusive supplier for Europe where launch is planned in 2012E with Astellas as marketing partner. Optimer received positive response from CHMP (Committee for Medicinal Products for Human Use) in September 2011. The European Commission generally follows the recommendations of the CHMP and delivers its final decision within three months of the CHMP opinion.